Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREVITY
2012-000214-11Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Jun 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by University of Birmingham. Primary endpoint: Primary: PET-defined complete response rate after 4 cycles. Started Jun 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2012-000214-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000214-11.